BTIG Research Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $30.00

MoonLake Immunotherapeutics (NASDAQ:MLTX) had its target price lifted by stock analysts at BTIG Research from $24.00 to $30.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective would suggest a potential upside of 64.84% from the company’s current price.

Several other analysts have also recently commented on the company. Zacks Research downgraded MoonLake Immunotherapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 20th. Citigroup downgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research note on Wednesday, October 29th. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, February 3rd. UBS Group set a $24.00 target price on MoonLake Immunotherapeutics in a research report on Friday, January 9th. Finally, The Goldman Sachs Group lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and lifted their price target for the company from $8.00 to $10.00 in a report on Wednesday, January 14th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $27.15.

MoonLake Immunotherapeutics Trading Down 2.6%

Shares of NASDAQ MLTX opened at $18.20 on Monday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -5.48 and a beta of 1.21. The stock’s 50 day moving average price is $15.38 and its two-hundred day moving average price is $23.61. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75.

Insider Activity

In other news, CEO Da Silva Jorge Santos sold 70,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the completion of the sale, the chief executive officer owned 2,878,577 shares of the company’s stock, valued at approximately $41,710,580.73. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Kristian Reich sold 72,908 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $14.43, for a total value of $1,052,062.44. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 402,908 shares of company stock worth $5,987,162. 12.05% of the stock is owned by insiders.

Institutional Trading of MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MLTX. Kestra Advisory Services LLC bought a new position in shares of MoonLake Immunotherapeutics in the 4th quarter worth $26,000. FNY Investment Advisers LLC acquired a new position in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at $28,000. Bank of America Corp DE increased its holdings in shares of MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after acquiring an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after acquiring an additional 3,166 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of MoonLake Immunotherapeutics by 45.4% during the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after purchasing an additional 1,069 shares during the period. 93.85% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Strong phase‑2 efficacy drove investor enthusiasm — sonelokimab showed high response rates in axSpA/chronic back‑pain programs (reported ~81% ASAS40 at Week 12) and S‑OLARIS data were highlighted at Investor Day, supporting the drug’s multi‑indication potential. MoonLake stock surges on positive axSpA trial data
• Positive Sentiment: Separate reports emphasize Phase‑2 chronic back pain success, which helped pre‑market gains and bolstered confidence into Investor Day. MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain
• Neutral Sentiment: Multiple analysts raised price targets and kept buy ratings (BTIG to $30, Needham to $25; other outlets reported increases), reflecting upside expectations if late‑stage programs progress. Benzinga analyst coverage
• Neutral Sentiment: Company released Investor Day materials (slides and transcript) and highlighted S‑OLARIS updates and program priorities — useful for modeling but not immediately dilutive. MoonLake Analyst/Investor Day – Slideshow
• Neutral Sentiment: Quarterly results showed EPS of ($0.97), in line with consensus but still a cash‑burning profile; that met expectations but leaves funding and profitability questions for longer‑term holders. Earnings press release
• Negative Sentiment: Mixed phase‑3 hidradenitis suppurativa (HS) readouts: VELA‑2 missed its primary endpoint, prompting at least one downgrade (Strong Buy → Buy). Although the FDA Type B meeting leaves a pathway to file a BLA using pooled data, the VELA‑2 miss increases regulatory and commercial execution risk. MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.